Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden

Show full item record



Permalink

http://hdl.handle.net/10138/334459

Citation

Hemminki , K , Försti , A , Hemminki , A , Ljungberg , B & Hemminki , O 2021 , ' Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden ' , PLoS One , vol. 16 , no. 6 , 0253236 . https://doi.org/10.1371/journal.pone.0253236

Title: Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
Author: Hemminki, Kari; Försti, Asta; Hemminki, Akseli; Ljungberg, Börje; Hemminki, Otto
Contributor organization: Department of Oncology
HUS Comprehensive Cancer Center
TRIMM - Translational Immunology Research Program
Clinicum
Research Programs Unit
University of Helsinki
HUS Abdominal Center
Urologian yksikkö
Date: 2021-06-22
Language: eng
Number of pages: 10
Belongs to series: PLoS One
ISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0253236
URI: http://hdl.handle.net/10138/334459
Abstract: Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.
Subject: NORDIC COUNTRIES
CANCER
IMPACT
DIAGNOSTICS
PREDICTION
TRENDS
END
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0253236.pdf 1.075Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record